Zucara Therapeutics Announces US$21 Million Series A Financing

Ontario Industry Updates
Written By Guest User
Zucara.jpg

Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent low blood glucose levels. It has announced that it has closed a US$21 million Series A Financing led by Perceptive Xontogeny Venture Fund.

Zucara will use the funding for Phase 1 and Phase 2 clinical trials of ZT-01, the company’s first-in-class drug candidate designed to prevent low blood glucose levels in Type 1 Diabetes.

Guest User
Previous

Self Care Catalysts Announces Health Storylines and Collaboration with Roche COVID-19 Data Science Coalition Project
Next

OBIO's COVID-19 Advocacy Efforts